BR0312173A - Mólecula de cdna, molécula e sequência de cdna recombinante, vetor, processo de preparação de partìculas de vìrus do sarampo infeccioso, composição imunogênica, composição de vacina e vìrus mononegaviral recombinante - Google Patents

Mólecula de cdna, molécula e sequência de cdna recombinante, vetor, processo de preparação de partìculas de vìrus do sarampo infeccioso, composição imunogênica, composição de vacina e vìrus mononegaviral recombinante

Info

Publication number
BR0312173A
BR0312173A BR0312173-9A BR0312173A BR0312173A BR 0312173 A BR0312173 A BR 0312173A BR 0312173 A BR0312173 A BR 0312173A BR 0312173 A BR0312173 A BR 0312173A
Authority
BR
Brazil
Prior art keywords
molecule
recombinant
sequence
vector
virus
Prior art date
Application number
BR0312173-9A
Other languages
English (en)
Other versions
BRPI0312173B1 (pt
BRPI0312173B8 (pt
Inventor
Frederic Tangy
Chantal Combredet
Valerie Labrousse-Najburg
Michel Brahic
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29716946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0312173(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Publication of BR0312173A publication Critical patent/BR0312173A/pt
Publication of BRPI0312173B1 publication Critical patent/BRPI0312173B1/pt
Publication of BRPI0312173B8 publication Critical patent/BRPI0312173B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/12—Mumps virus; Measles virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MOLéCULA DE cDNA, MOLéCULA E SEQuêNCIA DE cDNA RECOMBINANTE, VETOR, PROCESSO DE PREPARAçãO DE PARTìCULAS DE VìRUS DO SARAMPO INFECCIOSO, COMPOSIçãO IMUNOGêNICA, COMPOSIçãO DE VACINA E VìRUS MONONEGAVIRAL RECOMBINANTE". A presente invenção refere-se a uma molécula de cDNA que codifica a seq³ência de nucleotídeos da fita de (+) RNA antigenómica de comprimento total de um vírus do sarampo (MV) que se origina de uma linhagem de vacina aprovada. Ela também se refere à preparação de composições imunogênicas utilizando o mencionado cDNA.
BRPI0312173A 2002-06-20 2003-06-20 vetor e processo para a preparação de partículas infecciosas de vírus do sarampo BRPI0312173B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02291551A EP1375512B1 (en) 2002-06-20 2002-06-20 Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
EP02291551.6 2002-06-20
PCT/EP2003/007145 WO2004000876A1 (en) 2002-06-20 2003-06-20 INFECTIOUS cDNA OF AN APPROVED VACCINE STRAIN OF MEASLES VIRUS, USE FOR IMMUNOGENIC COMPOSITIONS

Publications (3)

Publication Number Publication Date
BR0312173A true BR0312173A (pt) 2005-04-05
BRPI0312173B1 BRPI0312173B1 (pt) 2019-05-07
BRPI0312173B8 BRPI0312173B8 (pt) 2021-05-25

Family

ID=29716946

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312173A BRPI0312173B8 (pt) 2002-06-20 2003-06-20 vetor e processo para a preparação de partículas infecciosas de vírus do sarampo

Country Status (15)

Country Link
US (3) US9005961B2 (pt)
EP (5) EP2110382A1 (pt)
KR (1) KR101227128B1 (pt)
CN (1) CN100577683C (pt)
AT (1) ATE437175T1 (pt)
AU (1) AU2003266950A1 (pt)
BR (1) BRPI0312173B8 (pt)
CA (1) CA2489052C (pt)
CY (1) CY1109506T1 (pt)
DE (1) DE60233038D1 (pt)
DK (2) DK1375512T3 (pt)
ES (2) ES2330309T3 (pt)
HK (1) HK1061568A1 (pt)
PT (1) PT1375512E (pt)
WO (1) WO2004000876A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
ATE437175T1 (de) * 2002-06-20 2009-08-15 Pasteur Institut Infektiöse cdna eines zugelassenen impfstammes des masern virus. verwendung in immunogenen zusammensetzungen
ES2427139T3 (es) * 2002-06-20 2013-10-29 Institut Pasteur Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
WO2009005917A2 (en) * 2007-05-29 2009-01-08 Vical Incorporated Methods of treating measles infectious disease in mammals
EP3037526B1 (en) * 2007-11-26 2018-03-14 London School of Hygiene and Tropical Medicine Method for producing vaccinal viral strain of a virus of the reoviridae family
EP2085479A1 (en) * 2008-01-31 2009-08-05 Institut Pasteur Reverse genetics of negative-strand rna viruses in yeast
EP2420242A1 (en) 2010-08-20 2012-02-22 Lauer, Ulrich M. Oncolytic measles virus
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
EP2712871A1 (en) 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
EP2759301A1 (en) 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
EP2959915A1 (en) 2014-06-23 2015-12-30 Institut Pasteur A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
EP3103474A1 (en) * 2015-06-12 2016-12-14 Institut Pasteur Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
JP6949468B2 (ja) * 2016-10-17 2021-10-13 ルプレヒト−カールス−ウニベルジテート ハイデルベルク 腫瘍抗原をコードする麻疹ウイルス
WO2018206512A1 (en) * 2017-05-09 2018-11-15 Invectys Recombinant measles vaccine expressing htert
EP3412307A1 (en) 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications
EP3707154A1 (en) 2017-11-09 2020-09-16 Institut Pasteur A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
SG11202004899SA (en) * 2017-12-21 2020-06-29 Pasteur Institut Lassa vaccine
CN111218475A (zh) * 2018-11-23 2020-06-02 成都生物制品研究所有限责任公司 一种拯救麻疹Schwarz/Moraten疫苗株的系统和方法
KR20220141332A (ko) * 2020-02-13 2022-10-19 앵스티띠 파스퇴르 홍역-벡터화된 covid-19 면역원성 조성물 및 백신
EP3865180A1 (en) * 2020-02-13 2021-08-18 Institut Pasteur Live recombinant measles virus expressing coronavirus antigens - its use in eliciting immunity against coronaviruses
EP3936517A1 (en) 2020-07-08 2022-01-12 Institut Pasteur An improved measles virus vaccine vector based on multiple tandem additional transcription units
AU2022208199A1 (en) 2021-01-13 2023-07-13 Centre National De La Recherche Scientifique Measles-hiv or measles-htlv vaccine
CN113293148B (zh) * 2021-03-10 2022-10-25 上海青赛生物科技有限公司 一种h基因替换的嵌合麻疹减毒株的构建
WO2022195900A1 (ja) * 2021-03-15 2022-09-22 国立大学法人東京大学 組換え麻疹ウイルス

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
JP3045581B2 (ja) 1991-10-14 2000-05-29 社団法人北里研究所 麻疹ワクチンウイルス株同定方法
DE69510207T3 (de) * 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
CA2265554A1 (en) * 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
JP4504464B2 (ja) 1997-02-28 2010-07-14 サノフィ パスツール バイオロジクス カンパニー キメラフラビウイルスワクチン
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6410023B1 (en) * 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
KR20010080863A (ko) * 1998-03-26 2001-08-25 윌리암 에이취 캘넌, 에곤 이 버그 마진 바이러스 또는 인간 호흡기 합포체 바이러스서브그룹 비에서 감쇠 담당 돌연변이
WO1999063064A1 (en) * 1998-06-03 1999-12-09 American Cyanamid Company Novel methods for rescue of rna viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
KR100884673B1 (ko) 1999-08-02 2009-02-18 와이어쓰 씨디엔에이로부터 멈프스 바이러스의 구제
HU229101B1 (en) * 2000-04-28 2013-07-29 St Jude Childrens Res Hospital Dna transfection system for the generation of infectious influenza virus
ES2427139T3 (es) 2002-06-20 2013-10-29 Institut Pasteur Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
ATE437175T1 (de) * 2002-06-20 2009-08-15 Pasteur Institut Infektiöse cdna eines zugelassenen impfstammes des masern virus. verwendung in immunogenen zusammensetzungen
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
EA027784B1 (ru) * 2008-05-26 2017-09-29 Кадила Хелзкэр Лимитед Комбинированная вакцина против кори и вируса папилломы человека
UA104180C2 (uk) * 2009-05-05 2014-01-10 Каділа Хелткере Лімітед Комбінована вакцина проти кору та малярії

Also Published As

Publication number Publication date
EP1375512A1 (en) 2004-01-02
EP1513872A1 (en) 2005-03-16
EP2311853A1 (en) 2011-04-20
HK1061568A1 (en) 2004-09-24
US9701944B2 (en) 2017-07-11
EP1375512B1 (en) 2009-07-22
US20150275184A1 (en) 2015-10-01
WO2004000876A8 (en) 2005-03-03
US20050227224A1 (en) 2005-10-13
BRPI0312173B1 (pt) 2019-05-07
DE60233038D1 (de) 2009-09-03
CA2489052C (en) 2014-07-29
AU2003266950A1 (en) 2004-01-06
KR101227128B1 (ko) 2013-01-29
CY1109506T1 (el) 2014-08-13
ES2330309T3 (es) 2009-12-09
CN1662553A (zh) 2005-08-31
US20130296541A1 (en) 2013-11-07
US9005925B2 (en) 2015-04-14
EP2110382A1 (en) 2009-10-21
EP2065393A1 (en) 2009-06-03
ES2663224T3 (es) 2018-04-11
KR20050058288A (ko) 2005-06-16
PT1375512E (pt) 2009-09-23
WO2004000876A1 (en) 2003-12-31
US9005961B2 (en) 2015-04-14
CA2489052A1 (en) 2003-12-31
DK1375512T3 (da) 2009-10-26
CN100577683C (zh) 2010-01-06
DK2311853T3 (en) 2018-04-16
EP2311853B1 (en) 2017-12-27
AU2003266950A8 (en) 2004-01-06
BRPI0312173B8 (pt) 2021-05-25
ATE437175T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
BR0312173A (pt) Mólecula de cdna, molécula e sequência de cdna recombinante, vetor, processo de preparação de partìculas de vìrus do sarampo infeccioso, composição imunogênica, composição de vacina e vìrus mononegaviral recombinante
ATE309821T1 (de) Influenzavirus-impfstoffzusammensetzung
BRPI0509683A (pt) vìrus de estomatite vesicular geneticamente modificado, vetor de vìrus da estomatite vesicular geneticamente modificado, composição imunogênica, e, métodos para imunizar um hospedeiro mamìfero contra infecção bacteriana e contra infecção viral
JP2008500399A5 (pt)
PL398576A1 (pl) Preparaty szczepionek, preparaty farmaceutyczne, atenuowany wirus grypy, sposoby szczepienia, sposoby zapobiegania chorobie zakaznej, sposoby leczenia lub profilaktyki nowotworów, kompozycje szczepionek i kompozycje farmaceutyczne
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
CY1112879T1 (el) Συνθεση εμβολιου
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
DK1373301T3 (da) Reducering af immunogeniciteten af fusionsproteiner
MX2009000650A (es) Vacunas para malaria.
WO2009026465A3 (en) Composition and methods of making and using influenza proteins
AR056133A1 (es) Virus de influenza canina y composiciones relacionadas y metodos de uso
PH12019500954A1 (en) Vaccine against porcine parvovirus
BRPI0616224B8 (pt) composição farmacêutica
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
BRPI0504945A8 (pt) Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
BR0312474A (pt) Partìcula viral adjuvante
MX2010006984A (es) Vacunas contra la malaria.
BR0207988A (pt) Cepas atenuadas vivas de vìrus de prrs
ATE303821T1 (de) Neue vakzinformulierung aus dna-vakzine- inaktiviertem virus
EA200200743A1 (ru) Рекомбинантное ослабление вируса репродуктивного и респираторного синдрома свиней (prrsv)
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
ATE426664T1 (de) Perorales impfstofftragersystem
ATE476197T1 (de) Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A RETRIBUICAO DA 9A ANUIDADE, DE ACORDO COM TABELA VIGENTE, REFERENTE A GUIA A GUIA DE RECOLHIMENTO 22110681725-1.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/06/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF